Showing results (181-190 of 230) with videos related to
Sort By:
Pageof 23
Gynecologic Oncology|March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safetyUrsula A Matulonis, Jørn Herrstedt, Amit Oza, et al.Gynecologic Oncology Reports|April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinomaElizabeth H Stover, Niya Xiong, Andrea P Myers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2012
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomeZhigang C Wang, Nicolai Juul Birkbak, Aedín C Culhane, et al.JCO Precision Oncology|April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial CancerPanagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.Expert Review of Anti-Infective Therapy|December 18, 2009
A clear and present danger: tick-borne diseases in EuropePaul Heyman, Christel Cochez, Agnetha Hofhuis, et al.Elife|November 14, 2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA TrialJosep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.Nature Immunology|May 20, 2026
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancerHan Dong, Arindam Ray, Lara K Rotter, et al.Pageof 23